The antinociceptive effects of intraplantar injections of 2‐arachidonoyl glycerol are mediated by cannabinoid CB2receptors
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background and purpose: 2‐arachidonoyl glycerol (2‐AG) is an endogenous cannabinoid with central antinociceptive properties. Its degradation is catalysed by monoacylglycerol lipase (MGL) whose activity is inhibited by URB602, a new synthetic compound. The peripheral antinociceptive effects of 2‐AG and URB602 in an inflammatory model of pain are not yet determined. We have evaluated these effects with and without the cannabinoid CB 1(AM251) and CB 2(AM630) receptor antagonists. Experimental approach: Inflammation was induced in rat hind paws by intraplantar injection of formalin. Nociception was assessed behaviourally over the next 60 min, in 19 experimental groups: (1) control; (2‐6) 2‐AG (0.01‐100 μg); (7) AM251 (80 μg); (8) AM251+2‐AG (10 μg); (9) AM630 (25 μg); (10) AM630+2‐AG (10 μg); (11‐16) URB602 (0.1‐500 μg); (17) 2‐AG+URB602 (ED 50); (18) AM251+URB602 (ED 50); (19) AM630+URB602 (ED 50). Drugs were injected s.c. in the dorsal surface of the hind paw (50 μl), 15 min before formalin injection into the same paw. Key results: 2‐AG and URB602 produced dose‐dependent antinociceptive effects for the late phases of the formalin test with ED 50 of 0.65±0.455 μg and 68±14.3 μg, respectively. Their combination at ED 50 doses produced an additive antinociceptive effect. These effects were inhibited by AM630 but not by AM251 for 2‐AG and by the two cannabinoid antagonists for URB602. Conclusions and implications: Locally injected 2‐AG and URB602 decreased pain behaviour in a dose‐dependent manner in an inflammatory model of pain. The antinociceptive effect of 2‐AG was mediated by the CB 2 receptor. British Journal of Pharmacology(2007)150, 693–701. doi:10.1038/sj.bjp.0706990
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 8×
“, 2005) whereas CB2 expression seems restricted to peripheral tissues with immune functions (Munro et al., 1993; Galiègue et al., 1995).”
BackgroundInfluentialMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“2-AG, an endogenous cannabinoid, is an agonist with a threefold selectivity for the CB1 receptor (Ki¼0.47 mM) over the CB2 receptor (Ki¼1.4 mM) (Lee et al., 1995; Mechoulam et al., 1995; Sugiura et al., 1996).”
BackgroundInfluentialIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“However, Kathuria et al. (2003) demonstrated that URB597, a selective FAAH inhibitor that greatly reduced anandamide degradation in the rat brain, had no effect on 2-AG levels.”
BackgroundLo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778 · cited 7×
“Thus, URB602, a non-competitive MGL inhibitor that blocks 2-AG hydrolysis was developed (Hohmann et al., 2005; Makara et al., 2005) and found to be more potent than URB597 in enhancing 2-AG levels and antinociception in stress models.”
BackgroundInfluentialFacci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632 · cited 2×
“Moreover, there are also reports on the presence of CB2 receptor mRNA in inflammatory and immune cells at levels 10–100 times those of CB1 receptor mRNA (Facci et al., 1995; Galiègue et al., 1995) and on peripheral nerve terminals (Pertwee et al.”
BackgroundIbrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Cannabinoid CB1 Receptor Expression in Rat Spinal Cord
Farquhar-Smith, W. P., Egertová, M., Bradbury, E. J., McMahon, S. B., Rice, A. S. C., & Elphick, M. R. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0844 · Cited by 268 · cited 2×
“The CB1 receptor is primarily expressed throughout the central nervous system including the spinal cord and on sensory neurons in dorsal root ganglia and in the periphery (Hohmann and Herkenham, 1999; Farquhar-Smith et al., 2000; Rice et al., 2002; Walczak et al., 2005) whereas CB2 expression seems restricted to perip…”
Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R., & Makriyannis, A. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00279-8 · Cited by 252 · cited 1×
“AM251 and AM630 are 306-fold (Gatley et al., 1996, 1997) and 70–165-fold (Pertwee et al., 1995; Hosohata et al., 1997; Ross et al., 1999; Malan et al., 2001) selective for CB1 and CB2 receptor antagonists, respectively.”
Background
Cited by
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Self-citationGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Self-citationChemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain
Baggelaar, M. P., Maccarrone, M., & van der Stelt, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.05.002 · Cited by 224
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G., Fowler, C. J., & Hohmann, A. G. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 218
“With respect to the peripheral component, local administration of both synthetic cannabinoids and exogenous anandamide and 2-AG produce antinociceptive effects in the formalin model of inflammatory pain (see e.g. Calignano et al., 1998; Guindon et al., 2007).”
Ghosh, S., Wise, L. E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B. F., & Lichtman, A. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.06.020 · Cited by 127
“Likewise, intra-paw administration of JZL184 or URB602 produced antinociceptive effects in the formalin model, which were blocked by CB1 and CB2 receptor antagonists (Guindon et al., 2007a, 2011).”
BackgroundComelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707425 · Cited by 97
“, 2006), whereas the anti-nociceptive effect in formalin test knew CB1 and CB2 mediation (Guindon et al., 2007).”
BackgroundInfluentialDesroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
“However, it seems to act mostly as a potent and full-efficacy agonist at the cannabinoid CB2 receptor (Gonsiorek et al., 2000; Guindon et al., 2007).”
BackgroundSelf-citationMecs, L., Tuboly, G., Toth, K., Nagy, E., Nyari, T., Benedek, G., & Horvath, G. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05346.x · Cited by 16
“allodynia and formalin-induced pain behaviour effectively by the activation of CB2 and ⁄ or CB1 receptors.(20,21) However, there is no data about its antinociceptive potency after its intraarticular administration.”
Background
Metadata
- Authors
- Guindon, J., Desroches, J., & Beaulieu, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-03
- Volume
- 150
- Issue
- 6
- Pages
- 693-701
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2069913986
- Cited by
- 100
- References
- 15
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.